FINWIRES · TerminalLIVE
FINWIRES

Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell

By

Replimune (REPL) said Sunday it is now evaluating RP2 in combination with nivolumab for metastatic uveal melanoma in a phase 2/3 trial based on results from the phase 1 trial.

The company said in its phase 1 first-in-human trial, RP2 monotherapy achieved an objective response rate of 19% in patients with advanced solid tumors. RP2 in combination with nivolumab had an objective response rate of 19.1%, it said.

In uveal melanoma, the pooled objective response rate, which included RP2 in combination with nivolumab and RP2 monotherapy, was 33.3%, it said.

The phase 1 first-in-human trial had enrolled 85 heavily pretreated patients with advanced solid tumors, including uveal melanoma, colorectal cancer, head and neck cancers, pancreatic cancer, cutaneous melanoma, and sarcoma, the company said.

Shares of the company were up over 13% in Monday's premarket activity.

Price: $9.90, Change: $+1.21, Percent Change: +13.92%

Related Articles

Wire

Revolution Medicines Says Phase 3 Daraxonrasib Trial Shows Survival Benefit in Metastatic Pancreatic Cancer

Revolution Medicines' (RVMD) phase 3 data for daraxonrasib showed improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer, the company said late Sunday.The phase 3 trial met all primary and key secondary endpoints, with daraxonrasib reducing the risk of death by 60% and increasing median overall survival to 13.2 months from about 6.6 months with chemotherapy, Revolution Medicines said.The once-daily oral therapy was generally well tolerated with a manageable safety profile, the company said.Revolution Medicines said it plans to submit data from the trial as part of its new drug application to the US Food and Drug Administration.Shares of Revolution Medicines were up over 10% in Monday premarket trading.Price: $174.50, Change: $+17.02, Percent Change: +10.81%

$RVMD
Wire

Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial

Summit Therapeutics' (SMMT) ivonescimab in combination with chemotherapy demonstrated a significant overall survival benefit over tislelizumab plus chemotherapy in the Phase III HARMONi-6 trial in previously untreated patients with advanced squamous non-small cell lung cancer, the company said Sunday.The company said ivonescimab reduced the risk of death by 34%, with patients receiving the drug plus chemotherapy achieving longer median overall survival and higher 24-month survival rates than those treated with tislelizumab plus chemotherapy.The survival benefit was consistent across both PD-L1-negative and PD-L1-positive patient groups. The study had previously met its primary endpoint of progression-free survival, the company added.The China-based trial, led by Akeso, showed no new safety concerns. Results were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The Lancet.Summit Therapeutics shares were up over 4% in Monday premarket activity.Price: $18.41, Change: $+0.87, Percent Change: +4.97%

$SMMT
Wire

Market Chatter: Pro Medicus' New Contracts Dispel Fears Over AI Competition, RBC Capital Markets Says

Pro Medicus' (ASX:PME) two recent contract awards in the US will help discredit fears of competitors in the artificial intelligence space eroding long-term demand, RBC Capital Markets said in a note, the Australian Financial Review reported Monday.The company disclosed that US subsidiary Visage Imaging renewed its partnership with Allegheny Health Network through a five-year contract valued at around AU$28 million, and also signed a seven-year contract with TidalHealth valued at AU$16 million.The contracts show that customers remain committed to longer term deals as opposed to shorter agreements that would maintain flexibility for AI-native alternatives, RBC analyst Jackson Lee said, according to the report.The awards also add to traction seen in the company's cloud imaging platform and transaction-based revenue model, RBC reportedly said.The investment firm kept a sector perform rating on Pro Medicus with a share price target of AU$195, AFR reported.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$ASX:PME